Prescription Opioid Abuse continues to be a significant and growing problem in the United States. According to the National Institute of Drug Abuse, more than 115 Americans die every day from an opioid overdose. Considering the graveness of the situation, this project aims at briefly studying the current trends and literature pertaining to the opioid epidemic and coming up with preventive measures. This was done by studying prevalent literature and data available on this subject to analyze patterns and trends of opioid addiction to help identify risk factors, using predictive modelling.

Headings:

- Predictive Modelling
- Risk Analysis
- Opioid Addiction
- Healthcare Analytics
PREDICTIVE MODELLING TO IDENTIFY RISK FACTORS LEADING TO OPIOID ADDICTION

by
Nidhi M. Shah

A Master’s paper submitted to the faculty of the School of Information and Library Science of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Master of Science in Information Science.

Chapel Hill, North Carolina
November 2018

Approved by

_______________________________________
David Gotz
Table of Contents

1. Introduction......................................................................................................................... 2
   1.1 Opioid Abuse .................................................................................................................. 2
   1.2 The Opioid Epidemic ..................................................................................................... 3
   1.3 Analyzing Electronic Health Records ............................................................................ 5
2. Literature Review .................................................................................................................. 6
   2.1 Opioid Abuse – History and Rising Importance .............................................................. 6
   2.2. Populations and Organizations Involved (and Affected) .............................................. 8
   2.3 Data Driven Solutions for the Opioid Epidemic .......................................................... 12
   2.4 Predictive Analytics on Medical Data .......................................................................... 14
3. Methods ............................................................................................................................. 16
   3.1. Data ............................................................................................................................. 16
   3.2 Data Cleaning and Manipulation .................................................................................. 17
   3.3 Predictive Modelling .................................................................................................... 21
4. Results and Discussion ..................................................................................................... 27
5. Conclusion and Future Work .............................................................................................. 38
Bibliography .......................................................................................................................... 40
1. Introduction

Prescription Opioid Abuse continues to be a significant and growing problem in the United States. According to the National Institute of Drug Abuse, more than 115 Americans die every day from an opioid overdose. The Substance Abuse and Mental Health Services Administration (SAMHSA) survey, has stated that non-medical use of prescription drugs is the second most prevalent type of drug abuse, after marijuana. In October of 2017, President Trump declared a public health emergency to combat the opioid epidemic. He also directed agency and department heads to use all appropriate emergency authority to reduce the number of deaths from opioids. President Obama had earmarked $1.1 billion dollars for developing solutions to this issue while he was in office.

Considering the graveness of the situation, this project aims at briefly studying the current trends and literature pertaining to the opioid epidemic and using data analytics to identify predictive risk factors for opioid addiction. This will be done by studying longitudinal electronic health data for patients with and without a history of opiate abuse. This data will be analyzed using predictive machine learning algorithms to identify risk factors for opioid addiction.

1.1 Opioid Abuse

Opioids are a class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone
(OxyContin®), hydrocodone (Vicodin®), codeine, morphine, and many others. These drugs are chemically related and interact with opioid receptors on nerve cells in the body and brain. Opioid pain relievers are generally safe when taken for a short time and as prescribed by a doctor, but because they produce euphoria in addition to pain relief, they can be misused (taken in a different way or in a larger quantity than prescribed or taken without a doctor’s prescription). Risks of using prescription opioids include dependence and addiction. The risks of dependence and addiction are higher if you abuse the medicines. Abuse can include taking too much medicine, taking someone else's medicine, taking it in a different way than you are supposed to, or taking the medicine to get high (MedlinePlus).

The misuse of and addiction to opioids—including prescription pain relievers, heroin, and synthetic opioids such as fentanyl—is a serious national crisis that affects public health as well as social and economic welfare. Although most people take prescription medications responsibly, an estimated 52 million people have used prescription drugs for nonmedical reasons at least once in their lifetimes. The Centers for Disease Control and Prevention estimates that the total "economic burden" of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.

1.2 The Opioid Epidemic

The opioid epidemic has its roots in the explosive growth of prescription painkillers. Between 1991 and 2011, the number of opioid prescriptions (selling under brand names like Vicodin, Oxycontin, and Percocet) supplied by American retail pharmacies increased from 76m to 219m. As the number of pain pills being doled out by
doctors increased, so did their potency. In 2002 one in six users took a pill more powerful than morphine. By 2012 it was one in three. Many of the victims’ hail from white middle-class suburbs and rural towns. The Data collected over the years shows that the problem is worsening with time.\(^6\)

Tackling the problem of accidental deaths due to Opioid abuse has become a top priority amongst many government as well as non-government bodies. Various bodies such as The U.S. Department for Health and Human Services (HHS), The National Institute on Drug Abuse (NIDA), The Centers for Disease Control and Prevention; insurance agencies (Blue Cross Blue Shield)\(^7\) as well as retail pharmacies (Walmart)\(^8\) throughout the country have deployed resources to monitor the opioid crisis and implement various policies to overcome this epidemic. Figure 1.0 below, shows the distributions of drugs involved in overdose deaths in the U.S. and we can clearly see that the death rate due to synthetic opioids has considerably shot up since 2013.

![Fig 1: Drugs Involved in U.S. Overdose Deaths](https://www.nih.gov/sites/default/files/about-nih/nih-director/statements/collins/20171026-opioid-statement.jpg)
The research (and consequent findings) carried out by the above-mentioned organizations has been briefly studied in the following chapters to gain a better understanding of the current situation in this crisis.

The nation’s opioid epidemic reflects a complex set of circumstances. The pattern of opioid prescribing—including dose and duration—and the patient’s risk factors of age, gender and condition are major determinants of whether a patient becomes dependent. Keeping in mind the research and efforts of various “key” organizations, this project aims at studying patient data and developing an interactive system that would set up predictors allowing monitoring of drug prescription as well as use. The literature review to support the theories, the methodology as well as the predictive algorithm and its features have been described in detail in the further chapters.

1.3 Analyzing Electronic Health Records

Health data is collected during a patients’ routine interactions with the medical care system within the patients’ electronic health record (EHR). The EHR specifically contains medications and diagnosis data, which record longitudinal (over time) history of opiate prescriptions and opiate dependency diagnoses, along with tens of thousands of other diagnoses.

This data should hold clues about risk factors associated with the development of opiate dependency. This project aims to identify leading factors via retrospective analysis of this routinely collected medical data.
2. Literature Review

This chapter provides an overview of previous research prescription drug abuse and data-driven preventive measures undertaken to combat it. It introduces the framework for the research and methodology that summarize the main goals of this project. It is important to set the context of the literature review work by first providing a brief history of opioid abuse and its rising importance. It will be followed by:

1. Identifying populations (and organizations) affected by the opioid epidemic;
2. Comments on current preventive measures being undertaken by the concerned organizations;
3. Case studies of data-driven approaches to fight the opioid epidemic and predictive analytics on health care data.

2.1 Opioid Abuse – History and Rising Importance

The opioid addiction epidemic is one of America’s foremost health crises. While the word “epidemic” is often overused, it is an apt description of the crisis brought on by opioid abuse in America. According to the most recent statistics from the Centers for Disease Control and Prevention (CDC), opioids (including prescription opioids and heroin) kill more than 33,000 people annually, which is more than any year on record and more than at the peak of the human immunodeficiency virus (HIV) epidemic. Opioid
abuse/overdose is considered a leading cause of shortened life expectancy in the U.S.\textsuperscript{11} According to the Substance Abuse and Mental Health Services Administration (SAMHSA) Survey, nonmedical use of prescription drugs is the second most prevalent type of drug abuse, after marijuana.

![THE OPIOID EPIDEMIC BY THE NUMBERS](https://www.hhs.gov/opioids/sites/default/files/inline-images/opioids-by-the-numbers-091918v.png)

Since 1999, prescriptions of opioids have almost quadrupled, as have the number of deaths involving opioids. According to the Centers for Disease Control and Prevention (CDC), drug overdose deaths have tripled from 1999–2014. In 2014, among 47,055 drug overdose deaths, 61\% involved an opioid. From 2014 to 2015, the death rate from synthetic opioids increased by 72.2\%.\textsuperscript{12} While prescriptions have increased substantially, the level of pain reported by Americans has not. Historically, illegal opioids, such as heroin, were
the primary contributing factor to overdoses. It could be said that prescribing practices are fueling opioid misuse which contributes significantly to the overdose epidemic.\textsuperscript{13}

\textbf{2.2. Populations and Organizations Involved (and Affected)}

While it is widespread in the United States of America, countries across the world are currently grappling with what is a global opioid crisis.\textsuperscript{14} Opioids were the most harmful drug type and accounted for 70\% of the negative health impact associated with drug use disorders worldwide, according to World Drug Report, released by the United Nations Office on Drugs and Crime (UNDOC).\textsuperscript{15} In its 2016 report, the International Narcotics Control Board (INCB), based in Vienna, Austria, noted with great concern, the largescale opioid, prescription drug and heroin abuse problem that continues to affect the United States, claiming tens of thousands of victims each year.\textsuperscript{16}

Considering the graveness of the situation, tackling the problem of accidental deaths due to Opioid abuse has become a top priority amongst many governmental as well as non-governmental organizations.

The United Nations and many of its subsidiaries are doing everything in their power to promote education and preventive measures about the rising opioid epidemic. Within the United States, bodies such as Center for Disease Control and Prevention (CDC), Health and Human Services (HHS), Department of Veterans, National Institute of Drug Abuse (NIDS), Substance Abuse and Mental Health Services Administration (SAMSHA) and various other government bodies (including individual state governments) are allocating funds towards finding solutions for the opioid crisis.
Many health insurance companies such as Blue Cross Blue Shield and retail pharmacies such as Walmart, CVS are also active participants in the fight against the opioid epidemic.

**Preventive Measures being Undertaken by Involved Organizations**

The misuse of prescription opioids and heroin can lead to a wide variety of problems, including overdose deaths, hospitalizations, and drug diversion arrests. To fully understand the impact of these problems, prevention practitioners collect data on a variety of prescription opioid- and heroin-related indicators—to inform their needs assessments, create epidemiological profiles and/or data tools, and select prevention priorities and target populations. This section, elaborates on the efforts taken by various international agencies; and governmental bodies within the United States to solve the opioid crisis.

*The International Narcotics Control Board & other United Nations Bodies*

In its 2016 Report, The International Narcotics Control Board approved the Drug Enforcement Administration’s comprehensive action plan to address opioid addiction and the allocation by the Government of $27.6 billion for the 2016 fiscal year to support the implementation of the 2015 National Drug Control Strategy. The Food and Drug Administration released the Opioids Action Plan in February 2016, in response to the ongoing crisis of opioid abuse, dependence and overdose in the United States. The plan includes expanding the use of advisory committees, strengthening requirements for drug companies to generate post-market data on the long-term impact of using opioids, updating risk evaluation and mitigation strategy programs, and expanding access to abuse-deterrent formulations to discourage abuse. As part of the action plan, class-wide safety labelling changes for immediate-release opioid pain medications have been announced.
The President of the United States requested $27.6 billion for the fiscal year 2016 to support efforts under the 2015 National Drug Control Strategy to reduce drug use and its effects in the country. Most of that amount was allocated to prevention and treatment efforts. In March 2016, the President requested from Congress an additional $1.1 billion to bolster efforts to address the prescription opioid and heroin crisis in the country. This represents further steps to expand access to treatment, prevent opioid overdose deaths, invest in community policing to address heroin abuse, and increase community prevention strategies.

Opioid overdose and heroin-related deaths have been the focus of state of the state addresses in a number of states of the United States. As of March 2016, 49 states had established prescription drug monitoring programs and 14 states had enacted legislation requiring physicians to receive training on the proper prescription of opioids.

On 22 July 2016, the Comprehensive Addiction and Recovery Act came into force. The Act addresses the opioid crisis by, inter alia, authorizing the United States Department of Justice to award grants to state, local and tribal governments to provide opioid abuse services, directs the Department of Veteran Affairs to expand its opioid safety initiative, focuses on helping communities develop treatment and overdose programs and addresses exemptions from criminal and civil liability for those administering an opioid overdose reversal drug or who contact emergency services in response to an overdose.

The National Institute on Drug Abuse dedicated a section of its website to resources about this opioid overdose reversal drug, including information about dosage,
precautions, side effects and links to pharmacies that offer it. The Administration has also been reviewing options, including making naloxone available over the counter, to make the drug more accessible for treating opioid overdose in the country. As at May 2016, 39 states allow prescribers to dispense a naloxone prescription to third parties, such as a family member of drug users.

In 2013, the cost of medical care and substance abuse treatment for opioid addiction and overdose was an estimated $78.5 billion, according to a report in the journal *Medical Care*.

Forty-nine states have prescription drug monitoring programs, databases which enable health care providers to curb "doctor shopping" by patients who obtain opioid prescriptions from multiple physicians. Missouri's program is not yet statewide but has enacted legislation to authorize it.

The 21st *Century Cures Act*, passed in 2016, allocated $1 billion over two years in opioid crisis grants to states, providing funding for expanded treatment and prevention programs. In April 2017, Health and Human Services Secretary Tom Price announced the distribution of the first round of $485 million in grants to all 50 states and US territories.

In August 2017, Attorney General Jeff Sessions announced the launch of an *Opioid Fraud and Abuse Detection Unit* within the Department of Justice. The unit's mission is to prosecute individuals who commit opioid-related health care fraud. The DOJ is also appointing US attorneys who will specialize in opioid health care fraud cases as part of a three-year pilot program in 12 jurisdictions nationwide.

State legislatures are also taking action, introducing measures to regulate pain clinics and limit the quantity of opioids that doctors can dispense.
2.3 Data Driven Solutions for the Opioid Epidemic

Data management and analysis can provide a broad spectrum of integrated solutions, from helping develop better treatment protocols, to enabling pharmacies to identify dispensing anomalies, and allowing large hospital systems and public health agencies to better analyze the possible outcomes of well-intentioned initiatives.\textsuperscript{25}

For any solutions, all individual groups mentioned above, need to work in tandem by sharing data and creating a flow of information. Fighting this epidemic is a highly complex challenge that requires a variety of players to collaborate in order to fully understand and solve the problem.

The research conducted by SAS \textsuperscript{25} states that most fundamentally, better data and analytics can help develop better treatment protocols, both for pain in the first place and for remediation when patients are becoming dependent on the drugs. Physicians want to know how their treatments and results compare with those of their peers, as well as what specific patterns give early warning of addiction or overdose. The CDC has issued guidelines about reevaluating chronic pain patients after three months, and Schedule 2 drugs (those with high potential for abuse or dependency) cannot be automatically refilled. But many patients demand opioids and are provided them by the system in unsafe quantities for long periods of time. Analytics help the physician recognize patient scenarios, prescribe correctly, and focus on the best overall outcome. Large hospital systems, licensing boards, and public health agencies need the ability to benchmark providers by specialty and get a better picture of where and how to educate them. These organizations are in the best position to aggregate data – PDMP, emergency room, hospitalization, medical examiner – and give providers that peer-to-peer comparison.
Analytics can inform treatment guidelines, educational initiatives, and resource allocations, including treatment centers and community prescription drug take-back programs. These organizations can also be better positioned to inform and influence policy makers at the state and national levels. Data and analytics should enable the organizations charged with leadership and policy to see more of the big picture and accelerate their decisions.

According to the study conducted by Blue Cross Blue Shield (BCBS)\(^6\), twenty-one percent of BCBS commercially-insured members filled at least one opioid prescription in 2015. Data also show BCBS members with an opioid use disorder diagnosis spiked 493 percent over a seven-year period. The report analyzes medical claims from BCBS commercially insured members diagnosed with opioid abuse disorder from 2010 through 2016 (Members diagnosed with cancer or who were undergoing palliative or hospice care were excluded from this analysis). Specifically, it looks at the degree of prescription opioid use—in terms of the dose and duration of opioid prescriptions—and how this relates to opioid dependence.

The Department of Justice is recruiting big data analytics to help combat opioid fraud and abuse in the healthcare system.\(^7\)

The Centre for Disease Control and Prevent believes that improving the nation’s big data analytics capabilities is critical for success in the ongoing fight against opioid abuse at the state level as the substance abuse epidemic continues to ravage communities on a massive scale.\(^8\)

While initiatives are being taken at every level be it by the government sector or the private, it is important to understand the brevity of the problem and come up with
analytical solutions for it. Using data to overcome such challenges is becoming more common these days.

### 2.4 Predictive Analytics on Medical Data

Healthcare analytics refers to the systematic use of health data and related business insights developed through applying analytical, e.g. statistical, contextual, quantitative, predictive, cognitive, and other models, to drive fact-based decision making for planning, management, measurement, and learning in healthcare ³⁹. At the same time, predictive analytics is believed to be the next revolution both in statistics and medicine around the world ³⁰.

**Predictive Analytics**

Predictive analytics involves using empirical methods (statistical and other) to generate data predictions as well as methods for assessing predictive power ³¹. The collection of methods in Predictive Analytics known as ‘data mining’ offers methodological and technical solutions to deal with the analysis of medical data and construction of prediction models ³². For this instance, predictive analytics can be used to identify high-risk patients and provide them treatment to reduce opioid addiction. Predictive Analytics uses a variety of statistical techniques such as modeling, machine learning, and data mining that analyze current and historical data to make predictions about the future.

For this project the predictive algorithms used include Logistic Regression and Random Forest (refer section on Predictive Modelling). In the context of low-dimensional
data (i.e. when the number of covariates is small compared to the sample size), Logistic Regression is considered a standard approach for binary classification. Since its invention 17 years ago, the random forest (RF) prediction algorithm, which focuses on prediction rather than explanation, is increasingly becoming a common “standard tool” also used by scientists without any strong background in statistics or machine learning.

**Electronic Health Record Systems**

Electronic health records (EHRs) systems, such as Epic, collect a range of data including demographics, medical history, medication and allergies, immunization status, laboratory test results, radiology images, vital signs, personal statistics like age and weight, and billing information. Large healthcare systems use this data for research and retrospective analytics. Carolina Data Warehouse for Health is one such organization. Construction of predictive models for disease targets across varying patient cohorts using EHRs has become increasing common in Healthcare analytics. Opioid Addiction being the target disease for this project, the EHRs of patients were segregated into 2 sections – EHRs of patients with a history of opioid addiction and EHRs of patients with no history of opioid addiction. This segregation was possible by using the ICD-10 system for diagnoses coding.

**ICD-10 System**

ICD-10 is the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. Patients with and without a past history of opioid addiction were identified using this coding system.
3. Methods

The goal of this project was to develop a model that could highlight and predict factors leading to opioid addiction among patients. The predictive model was be built using patient diagnosis data, while the patient medication data gave additional insights into addiction patterns. The following sections expand on the data used for this project and the predictive modelling algorithms that were applied to achieve a high level of accuracy in predicting opioid addiction among patients.

3.1. Data

Data Source

In order to assess distribution ad use of opioids among the population in the United States, limited patient data from the Carolina Data Warehouse for Health (CDW-H) was analyzed. The most identifiable features were omitted from the data set and artificial patient IDs were used to link variables across a single patient. However, this mapping was performed by NC TraCS analysts and was not shared with the research team.

To minimize the risk of a breach of confidentiality, the data is stored on NC TraCS provisioned and maintained secure storage which is a Level III Data Security environment and has been approved for such use with data from the CDW-H.

Feature Description

The dataset from CDW-H comprised of deidentified patient data from three different cohorts – COPD, Diabetes and Heart Failure. Each cohort was further divided
into three datasets – patient events, patient medication, and patient demographics. They have been described in detail below. Each dataset had a common patient id or a deid (deidentified id) that linked the three datasets together. Additionally, the data came with a Data Guide that included a summary of the data provision, a data dictionary for each file provisioned, and entity relationship diagrams (ERD). Considering unique patients from each of the three cohorts, the datasets contained records for 20,291 unique patients.

Patient Events

This dataset comprised of the deidentified patient ID, date (date on which the procedure was done or diagnosis was made), codeclass (procedure/diagnosis), and code. These three features together made up a unique event for any patient.

Patient Medication

This dataset comprised of several columns such as Patient – id, cohort, age; visit_id, medication is, medication name, medication brand name, generic drug description, drug strength, dosage formulation etc.

Patient Demographics

This dataset comprised on general demographic information such as patient id, age, sex, and race without divulging personal identifiable information.

3.2 Data Cleaning and Manipulation

Data cleansing or data cleaning is the process of detecting and correcting (or removing) corrupt or inaccurate records from a record set, table, or database and refers to identifying incomplete, incorrect, inaccurate or irrelevant parts of the data and then replacing, modifying, or deleting the dirty or coarse data. Data cleansing may be performed interactively with data wrangling tools, or as batch processing through scripting.
While all three datasets were used for initial data exploration, the datasets used to build the predictive model were Patients Events and Patient Medication and the data cleaning and manipulation was done in Python. The general algorithm to clean and manipulate these datasets has been specified below.

**Patient Events:**

*Step 1: Load data and Create Pandas Dataframe*

Firstly, the events.csv files for all cohorts (COPD, DM and HF) were combined into one pandas dataframe and dropped all duplicate rows since there were many patients who existed in multiple cohorts.

*Step 2: Filter Dataframe*

Next, the master dataframe was filtered on codeclass=ICD10CM since we were only interested in the ICD10 diagnosis codes and not procedure.

*Step 3: Feature Reduction*

1. Drop unnecessary variables: The date and codeclass variables were dropped from the dataframe as they would not be informative in building the predictive model.

2. Restructure hierarchy: The code variable was then manipulated to include all sub-codes for a given code into the parent code. For example: F11.01, F11.09 fell under F11 and so on. This helped in reducing the number of features. Since this step generated duplicate values, they were again dropped at this stage.

*Step 4: Identify Unique Patients*

1. Identified all unique patients in the master dataframe and created a list of the same.

   Total number of unique patients: 202190
2. Identified patients that were diagnosed with Opioid Addiction (ICD10 code for Opioid Dependency – F11 39,41) and created a list of the same.

3. Total number of unique patients diagnosed with opioid addiction:

4. Created a list of unique patients not diagnosed with opioid addiction by subtracting the list of patients diagnosed with opioid addiction from the list of all unique patients.

![Number of Non-Opioid Addicted Patients: 29993
Number of Opioid Addicted Patients: 863]

**Fig 3: Spread of opioid addicted and non-opioid addicted patients in the master dataset**

**Step 5: Create Dataframe of Opioid Addicted and Non-Opioid Addicted Patients**

Comparatively, only a small subset of patients within the master dataset were diagnosed with opioid addiction. For a robust predictive model, it is important to have equal number of entries for the target variable. In this case, opioid addiction being the target variable, it was important to create a dataframe that had equal number of patients diagnosed with opioid addiction as well as patients not diagnosed with opioid addiction and include all instances of these patients from the master dataframe.
Step 6: Binary Encode and Group by patient id

Predictive models accept data in certain format. Most models require categorical variables to be encoded. Since the dataframe contains all categorical variables (all diagnosis codes are categorical), it was important to binary encode them. After binary encoding the diagnosis codes and grouping them by patient id, codes that appeared less than 5 times in the entire dataframe were dropped.

<table>
<thead>
<tr>
<th>id</th>
<th>code</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>I10</td>
</tr>
<tr>
<td>1</td>
<td>J34</td>
</tr>
<tr>
<td>2</td>
<td>N39</td>
</tr>
<tr>
<td>3</td>
<td>R05</td>
</tr>
<tr>
<td>4</td>
<td>Z79</td>
</tr>
<tr>
<td>5</td>
<td>Z12</td>
</tr>
<tr>
<td>6</td>
<td>Z08</td>
</tr>
<tr>
<td>7</td>
<td>Z85</td>
</tr>
</tbody>
</table>

Fig 4: Dataset before binary encoding

<table>
<thead>
<tr>
<th>id</th>
<th>code_A04</th>
<th>code_A08</th>
<th>code_A09</th>
<th>code_A15</th>
<th>code_A31</th>
<th>code_A40</th>
<th>code_A41</th>
<th>code_A52</th>
<th>c</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>1111</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>2222</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>3333</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>4444</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>5555</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>6666</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>7777</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>8888</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>9</td>
<td>9999</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Fig 5: Dataset after binary encoding
Step 7: Explore the dataset and proceed to building the predictive model
The final dataframe consisted of 958 variables - 957 diagnosis codes and the patient id variable, and 1726 rows.

![Clean and Transformed Dataset](image.png)

*Fig 6: Equal number of opioid addicted and non-opioid addicted patients.*

As we can see in the figure above, the dataset consisted of 863 patients diagnosed with opioid addiction and 863 patients not diagnosed with opioid addiction.

Finally, the cleaned and transformed dataframe was saved as a csv file and ready to be used to build the predictive model.

3.3 Predictive Modelling

Predictive modelling uses statistics to predict outcomes. Most often the event one wants to predict is in the future, but predictive modelling can be applied to any type of unknown event, regardless of when it occurred. Nearly any regression model can be used for prediction purposes. Broadly speaking, there are two classes of predictive models: parametric and non-parametric. Parametric models make "specific assumptions with regard to one or more of the population parameters that characterize the underlying distribution(s)", while non-parametric regressions make fewer assumptions than their
parametric counterparts. Since we would like to predict opioid addiction (assumption) using diagnosis and medication data (parameters) for the given patients (population), the models we will use are parametric in nature.

In predictive modelling most of the time is spent understanding the requirements and then framing the problem. The next step is to tailor the solution to the needs. Generally, a framework can be used to build the first cut of models. Python is a useful tool since it has a large number of open source libraries for predictive analytics and data science, making it a good choice for building the predictive models for this study. The various libraries used during data cleaning, and model building are: pandas, numpy, scipy, sklearn, etc.

Building the Model

**Step 1: Drop Variables not important for prediction**

The id feature in our dataframe did not contribute towards the prediction and was dropped.

**Step 2: Create list of features and identify Target Variable**

The remaining variables are features that will be used for building the predictive model. the outcome we wish to predict is opioid addiction (code: F11) making it our target variable.

```python
#--- DROP ID COL AS IT WILL NOT BE USED FOR REGRESSION
df = df.drop(df.columns[0], axis=1)

#--- CREATE LIST OF COLUMN NAMES TO BE USED AS TRAINING FEATURES
features = list(df.columns.values)

#--remove our target variable code_F11 from the list of features.
features.remove('code_F11')

#--assign target column
target = 'code_F11'
```

*Fig 7: Python code snippet for Steps 1 and 2*
Step 3: Split the dataframe into train and test

The dataframe was split into train and test. The training set contains the known target variable – opioid addiction, allowing the model to learn on this data in order to be generalized to other data later on. The test dataset is used to test our model’s prediction on this subset.

![Fig 7: Dividing the dataset into training and test data](image)

Step 4: Fit the train and test datasets

The dataset was then fit against a logistic regression and random forest model (after specifying a ten-fold cross validation) respectively to make the prediction. After dropping the id column, assigning the target variable and splitting the dataset into train and test data, the shape of the train and test sets is shown in Table 1.

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Rows</th>
<th>Columns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Train_x</td>
<td>1380</td>
<td>956</td>
</tr>
<tr>
<td>Train_y</td>
<td>1380</td>
<td>-</td>
</tr>
<tr>
<td>Test_x</td>
<td>346</td>
<td>956</td>
</tr>
<tr>
<td>Test_y</td>
<td>346</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 1: Train and Test Datasets

At this point, we were ready to run our chosen predictive models. The first model that was run was the Logistic Regression.

Logistic Regression

Logistic regression is a statistical method for analyzing a dataset in which there are one or more independent variables (diagnosis codes) that determine an outcome. In logistic regression, the dependent variable (target variable – opioid addiction) is binary or
dichotomous, i.e. it only contains binary encoded data (the reason why we binary encoded our dataset). The goal of logistic regression is to find the best fitting to describe the relationship between the dependent and the independent variables.\textsuperscript{45,46}

To build the logistic regression model, the sklearn library in python was used. First, the Logistic Regression module was imported and a Logistic Regression classifier object was created using LogisticRegression() function. Then, the model was fit on the train set using fit() and prediction was performed on the test set using predict().

![Python Code snippet for Logistic Regression Model.](image)

The model was evaluated using success metrics in the form of a confusion matrix, the accuracies scores, and precision and recall scores. The results for the same have been discussed in detail in the results and evaluation sections.

![Python Code snippet to check Logistic Model Performance and Accuracy](image)
**Random Forest**

Random Forest is an ensemble of unpruned classification or regression trees created by using bootstrap samples of the training data and random feature selection in tree induction. Prediction is made by aggregating (majority vote or averaging) the predictions of the ensemble \(^4\). Thus, given data on predictor variables (inputs, X) and a continuous response variable (output, Y) Random Forest builds a model for: 1. Predicting the value of the response from the predictors. 2. Understanding the relationship between the predictors and the response \(^5\). To say it in simple words: Random forest builds multiple decision trees and merges them together to get a more accurate and stable prediction.

The random forest regression model from scikit-learn imported, instantiated, and fit (scikit-learn’s name for training) on the training data.

```python
# Import Random Forest model from sklearn
from sklearn.ensemble import RandomForestRegressor

# Instantiate model with 1000 decision trees/estimators
rf = RandomForestRegressor(n_estimators = 1000, random_state = 42)

# Train the model on training data
rf.fit(train_X, train_y);
```

*Fig 11: Python Code snippet for Random Forest Model.*

Having trained the model on the training dataset, the next step was figuring out how good the model was. This was done by making predictions on the test dataset. The predictions were then compared to the known answers. Ten-fold cross validation was used to measure the root mean squared error for the random forest prediction.

```python
# Running 10 fold cross validation to measure root mean squared error
scorer = make_scorer(mean_squared_error, False)
cv_score = np.sqrt(-cross_val_score(estimator= rf,
    X= train_X, y= train_y, cv=10, scoring = scorer))
rmse = cv_score.mean()
```

*Fig 12: Python Code snippet for Random Forest Prediction and root mean square error*
Random Forest is not the best choice for this study since the response variable is categorical and not continuous. However, a great quality of the random forest algorithm is that it is very easy to measure the relative importance of each feature on the prediction \(^{49}\).

The Random Forest Model helps understand feature significance i.e. – which features contribute the most towards the prediction. For this study, it is the feature significance that is of interest as opposed to the prediction itself. Similar to Logistic Regression, the Random Forest model was also built using the sklearn library in Python. Sklearn provides a great tool for this, that measures a features importance by looking at how much the tree nodes, which use that feature, reduce impurity across all trees in the forest. It computes this score automatically for each feature after training and scales the results, so that the sum of all importance is equal to 1.

```python
# Investigating feature importance with Random Forest
rf.fit(train_x, train_y)
coef = pd.Series(rf.feature_importances_,
                 index = train_x.columns).sort_values(ascending=False)
```

*Fig 13: Python Code snippet for investigating feature importance with Random Forest*

The next section expands on the results and evaluation of the predictive models.
4. Results and Discussion

Having built the predictive models, the next step was to look at the results.

**Logistic Regression**

Logistic Regression describes and estimates the relationship between one dependent binary variable and independent variables. This gave a binary prediction for opioid addiction. That is, it predicted a yes or no outcome for opioid addiction for a given patient. The first run of the Logistic Regression model yielded the following results:

**Model Accuracy**

The logistic regression model was trained on the training data and gave a 97% accuracy. The test data was used to make the prediction. When the trained model was run on the test data, it gave an accuracy of 79%. This means that 79% of the predictions made on the test data were accurate.

**Confusion Matrix**

A confusion matrix is a table with two rows and two columns that reports the number of false positives, false negatives, true positives, and true negatives. This allows more detailed analysis than mere proportion of correct classifications (accuracy).

<table>
<thead>
<tr>
<th></th>
<th>Predict No</th>
<th>Predict Yes</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actual No</td>
<td>142</td>
<td>37</td>
<td>179</td>
</tr>
<tr>
<td>Actual Yes</td>
<td>31</td>
<td>136</td>
<td>167</td>
</tr>
<tr>
<td>Total</td>
<td>173</td>
<td>173</td>
<td>346</td>
</tr>
</tbody>
</table>

*Table 2: Logistic Regression Confusion Matrix*
Table 2 shows the confusion matrix for the logistic regression model. It shows that the logistic regression model predicted 142 True Positive values, 37 False Positive values, 31 False Negative Values and 136 True Negative values. The goal is to build a model that has minimum False Positive and False Negatives to reduce Type I and Type II errors respectively.

*Classification Report – Precision, Recall, F-1 score*

Precision is intuitively the ability of the classifier to not label a sample as positive if it is negative. Recall is intuitively the ability of the classifier to find all the positive samples. The F-beta score can be interpreted as a weighted harmonic mean of the precision and recall, where an F-beta score reaches its best value at 1 and worst score at 0. The F-beta score weights the recall more than the precision by a factor of beta. beta = 1.0 means recall and precision are equally important. The support is the number of occurrences of each class in the target variable for the test data.

<table>
<thead>
<tr>
<th></th>
<th>Precision</th>
<th>Recall</th>
<th>F-1 score</th>
<th>Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.82</td>
<td>0.79</td>
<td>0.81</td>
<td>179</td>
</tr>
<tr>
<td>1</td>
<td>0.79</td>
<td>0.81</td>
<td>0.80</td>
<td>167</td>
</tr>
<tr>
<td>Total</td>
<td>0.80</td>
<td>0.80</td>
<td>0.80</td>
<td>346</td>
</tr>
</tbody>
</table>

*Table 3: Logistic Regression Classification Report – Precision, Recall, F-1 score*

*Root Mean Square Error*

The root mean squared error for the Logistic Regression Model was 0.44.

*Random Forest*

An advantage of random forest is that it can be used for both regression and classification tasks and it is easy to view the relative importance it assigns to the input features. We will now discuss the results of the random Forest Model.
**Root Mean Square Error**

Ten-fold cross validation was used to measure the root mean squared error for the random forest prediction.

![Cross Validation Score: Random Forest](image1)

*Fig 14: Random Forest Model: Cross Validation Iterations and Score*

The root mean squared error for the Random Forest Model was 0.36.

**Feature Significance**

As stated in the model building section, the random forest model was chosen for the feature significance module it provides. The model allowed plotting a feature significance graph to understand which of the variables (features) contributed the most towards the prediction. Fig 15 shows the top 10 predictive features for the model.

![Feature Significance](image2)

*Fig 15: Random Forest Model: Feature Significance*
Discussion

Using Fig 15 and the ICD 10 coding system\textsuperscript{39, 41}, we can determine which diagnosis codes contributed the most towards opioid addiction.

<table>
<thead>
<tr>
<th>Rank</th>
<th>Diagnosis Code</th>
<th>Description (from the ICD 10 coding system)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>G89</td>
<td>Acute pain</td>
</tr>
<tr>
<td>2</td>
<td>F19</td>
<td>Other psychoactive substance related disorders</td>
</tr>
<tr>
<td>3</td>
<td>F14</td>
<td>Cocaine related disorders</td>
</tr>
<tr>
<td>4</td>
<td>F18</td>
<td>Inhalant related disorders</td>
</tr>
<tr>
<td>5</td>
<td>F17</td>
<td>Nicotine dependence</td>
</tr>
<tr>
<td>6</td>
<td>F41</td>
<td>Other anxiety disorders</td>
</tr>
<tr>
<td>7</td>
<td>R52</td>
<td>Pain, unspecified</td>
</tr>
<tr>
<td>8</td>
<td>M96</td>
<td>Intraoperative and postprocedural complications and disorders of musculoskeletal system, not elsewhere classified</td>
</tr>
<tr>
<td>9</td>
<td>F13</td>
<td>Sedative, hypnotic, or anxiolytics related disorders</td>
</tr>
<tr>
<td>10</td>
<td>E78</td>
<td>Disorders of lipoprotein metabolism and other lipidemias</td>
</tr>
</tbody>
</table>

Table 4: Ranked Diagnosis codes and their description.

(Derived from: Feature Significance for Random Forest Model)

From Table 4 we can see that patients diagnosed with Acute Pain were more prone to opioid addiction. The table also shows that patients diagnosed with other addiction or dependencies, such as cocaine, nicotine, etc. were also more susceptible to opioid addiction. While these results are not surprising, they lead one to believe that most cases of opioid addiction stem from being prescribed opioid medication since Acute Pain is ranked first in the list of important features. What would the results look like if we were to run the predictive models solely on patients diagnosed with Acute Pain?

The next section elaborates on the results of the second run of predictive models on patients diagnosed with Acute Pain.
Predictive Models for Patients Diagnosed with Acute Pain

Similar to the first run of predictive model building, the second run followed the same basic steps, except being filtered for patients diagnosed with Acute Pain. There were total 941 patients in the dataset.

<table>
<thead>
<tr>
<th>Dataset</th>
<th>Rows</th>
<th>Columns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Train_x</td>
<td>752</td>
<td>956</td>
</tr>
<tr>
<td>Train_y</td>
<td>752</td>
<td>-</td>
</tr>
<tr>
<td>Test_x</td>
<td>189</td>
<td>956</td>
</tr>
<tr>
<td>Test_y</td>
<td>189</td>
<td>-</td>
</tr>
</tbody>
</table>

*Table 5: Train and Test Datasets for Predictive Modelling for patients diagnosed with Acute Pain.*

Logistic Regression (for patients diagnosed with Acute Pain)

The results and the success metrics for the Logistic Regression Model for patients diagnosed with Acute Pain were as follows:

*Model Accuracy*

The logistic regression model was trained on the training data and gave an accuracy of 99%. When the trained model was run on the test data, it gave an accuracy of 78%. This means that 78% of the predictions made on the test data were accurate.

*Confusion Matrix*

Table 6 shows the confusion matrix for the logistic regression model for patients diagnosed with Acute Pain. It shows that the logistic regression model predicted 26 True Positive values, 26 False Positive values, 15 False Negative Values and 122 True Negative values. Again, the goal is to build a model that has minimum False Positive and False Negatives to reduce Type I and Type II errors respectively.
Table 6: Logistic Regression Confusion Matrix (for Patients diagnosed with Acute Pain)

Classification Report – Precision, Recall, F-1 Score

Table 7 shows the Precision, Recall, and F-1 score for the logistic regression model.

<table>
<thead>
<tr>
<th></th>
<th>Predict No</th>
<th>Predict Yes</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actual No</td>
<td>26</td>
<td>26</td>
<td>52</td>
</tr>
<tr>
<td>Actual Yes</td>
<td>15</td>
<td>122</td>
<td>137</td>
</tr>
<tr>
<td>Total</td>
<td>41</td>
<td>148</td>
<td>189</td>
</tr>
</tbody>
</table>

Root Mean Squared Error

The root mean squared error for the Logistic Regression Model was 0.47. An error closer to 0 is generally preferable.

Random Forest for patients diagnosed with Acute Pain

The results and the success metrics for the Random Forest Model for patients diagnosed with Acute Pain were as follows:

Root Mean Squared Error

The mean squared error for the Random Forest Model for Patients diagnosed with Acute Pain (Ten-fold cross-validation as before) was 0.4
Again, the Random Forest Model allowed plotting a feature significance graph to understand which of the variables (features) contributed the most towards the prediction. Fig 17 shows the top 10 predictive features for the model.
As before, using Fig 17 and the ICD 10 coding system\textsuperscript{39,41}, we can determine which diagnosis codes contributed the most towards opioid addiction in patients diagnosed with Acute Pain.

<table>
<thead>
<tr>
<th>Rank</th>
<th>Diagnosis Code</th>
<th>Description (from the ICD 10 coding system)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F19</td>
<td>Other psychoactive substance related disorders</td>
</tr>
<tr>
<td>2</td>
<td>F17</td>
<td>Nicotine dependence</td>
</tr>
<tr>
<td>3</td>
<td>M96</td>
<td>Intraoperative and post procedural complications and disorders of musculoskeletal system, not elsewhere classified</td>
</tr>
<tr>
<td>4</td>
<td>F33</td>
<td>Major depressive disorder, recurrent</td>
</tr>
<tr>
<td>5</td>
<td>R52</td>
<td>Pain, unspecified</td>
</tr>
<tr>
<td>6</td>
<td>F41</td>
<td>Other anxiety disorders</td>
</tr>
<tr>
<td>7</td>
<td>Z01</td>
<td>Encounter for other special examination without complaint, suspected or reported diagnosis</td>
</tr>
<tr>
<td>8</td>
<td>M54</td>
<td>Dorsalgia</td>
</tr>
<tr>
<td>9</td>
<td>I49</td>
<td>Other cardiac arrhythmias</td>
</tr>
<tr>
<td>10</td>
<td>J32</td>
<td>Chronic sinusitis</td>
</tr>
</tbody>
</table>

Table 8: Ranked Diagnosis codes for patients diagnosed with Acute Pain and their description.
(Derived from: Feature Significance for Random Forest Model for Patients diagnosed with Acute Pain)

Comparing Table 7 (ranked diagnosis codes from the Random Forest model) and Table 8 (ranked diagnosis codes from the Random Forest model for patients diagnosed with Acute Pain), we can see that while some diagnosis codes appear in both the tables, many diagnosis codes are dismissed and new diagnosis codes appear in their place when we filter the dataset on patients diagnosed with Acute Pain. Table 9 describes the difference in the diagnosis code rankings for both the Random Forest Models.
<table>
<thead>
<tr>
<th>Rank</th>
<th>All Patients</th>
<th>DX_Code</th>
<th>Description</th>
<th>Patients Diagnosed with Acute Pain</th>
<th>DX_Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>G89</td>
<td>Acute pain</td>
<td></td>
<td>F19</td>
<td>Other psychoactive substance related disorders</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>F19</td>
<td>Other psychoactive substance related disorders</td>
<td></td>
<td>F17</td>
<td>Nicotine dependence</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>F14</td>
<td>Cocaine related disorders</td>
<td></td>
<td>M96</td>
<td>Intraoperative and postprocedural complications and disorders of musculoskeletal system, not elsewhere classified</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>F18</td>
<td>Inhalant related disorders</td>
<td></td>
<td>F33</td>
<td>Major depressive disorder, recurrent</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>F17</td>
<td>Nicotine dependence</td>
<td></td>
<td>R52</td>
<td>Pain, unspecified</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>F41</td>
<td>Other anxiety disorders</td>
<td></td>
<td>F41</td>
<td>Other anxiety disorders</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>R52</td>
<td>Pain, unspecified</td>
<td></td>
<td>Z01</td>
<td>Encounter for other special examination without complaint, suspected or reported diagnosis</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M96</td>
<td>Intraoperative and postprocedural complications and disorders of musculoskeletal system, not elsewhere classified</td>
<td></td>
<td>M54</td>
<td>Dorsalgia</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>F13</td>
<td>Sedative, hypnotic, or anxiolytics related disorders</td>
<td></td>
<td>I49</td>
<td>Other cardiac arrhythmias</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>E78</td>
<td>Disorders of lipoprotein metabolism and other lipidemias</td>
<td></td>
<td>J32</td>
<td>Chronic sinusitis</td>
<td></td>
</tr>
</tbody>
</table>

Table 9: Comparison of Table 7 and Table 8 – Ranked Diagnosis Codes generated from Feature Significance module of the Random Forest models

Table 9 gives a clear distinction of the difference in ranked diagnosis codes once we filter the dataset for patients diagnosed with Acute Pain. There is clear distinction between codes that did not get carried forward, the codes that were carried forward and the new codes that were seen in the new ranked list. The list of significant features generated
from the Random Forest model run on the main dataset (not filtered for patients diagnosed with Acute Pain) contained diagnosis codes for other dependencies (refer to Table 7). While some of these dependency diagnosis codes such as F19 (Other psychoactive substance related disorders) and F17 (Nicotine Dependency) were passed along, diagnosis codes related to anxiety and other psychological disorders cropped up in the new Table (refer to Table 8). This leads one to question the influence of psychological disorders on opioid addiction.

**Exploring the Patient Medication Dataset**

Based on the results of the predictive models, it was advisable to look at the Patient Medication Dataset to draw further insights.

*Insights from Patient Medication Dataset*

The subjects of interest in the Patient Medication dataset were patients who were prescribed opioids. Thus, the medication dataset was filtered for patients that were prescribed opioids.

The list of opioids used to filter the dataset was:

- Fentanyl
- Methadone
- Morphine
- Oxycodone
- Hydrocodone
- Demerol
- Percocet
- Oxycodone
- Vicodin
- Heroin
- Duragesic
- Roxicodone
- Darvocet
- Lorcet
This list was derived from the National Institute on Drug Abuse. It is important to understand that many of these drugs share the same parent drug and could just be different brand names for the same generic drug.

Within the dataset, the opioids found were:

- Fentanyl
- Methadone
- Morphine
- Oxycodone
- Hydrocodone
- Oxycodone
- Oxycontin
- Vicodin

While it was difficult to gleam information and draw insights from initial exploration of the Patient Medication dataset, it would prove to be useful to study this dataset further and include those variables in building the predictive model. The drugs patients are prescribed along with the duration they have been on said drug could significantly contribute towards predicting opioid addiction.
5. Conclusion and Future Work

Prescription opioid abuse is inherently dangerous and may lead users down a path towards serious, illicit drug abuse and addiction problems. Efforts to curb the prescription opioid abuse problem are challenged by numerous factors that all relate to the way that these medications are perceived in the public sphere. Despite their legal status, opioid medications have a very high potential for abuse and addiction and are being overprescribed at alarming rates.\textsuperscript{52}

Fortunately, people are beginning to realize the brevity of the situation and necessary steps are being taken address this issue. Educating people, both professional and consumers, of the underlying causes of this epidemic, will make them better equipped to address the major public health concerns arising from opioid abuse.

Analyzing data related to patients diagnosed with opioid addiction has led to identifying risk factors that lead to opioid addiction. The predictive model built is based solely on past patient diagnosis history. However, there are numerous other factors that can contribute towards addiction. It would be useful to study the patient medication history to gain further insights and narrow down the risk factors. Past research has shown that patient demographics (age, gender, race, socio-economic status) could also contribute towards addiction. Adding these variables to the predictive model could yield better results and give a deeper understanding of the risk factors leading to opioid addiction.
This project is another such attempt at providing a solution to the opioid epidemic. Prevention is always better than cure and addressing the risk factors leading to opioid addiction would help overcome the epidemic on a whole.
Bibliography


overdose deaths in the United States continue to increase in 2015. Retrieved from:
https://www.cdc.gov/drugoverdose/epidemic/


Vienna, Austria. Retrieved from:
http://www.incb.org/documents/Publications/AnnualReports/AR2016/English/AR
2016_E_ebook.pdf

https://www.drugabuse.gov/drugs-abuse/opioids

Public Health Impact into the Formal Risk-Benefit Assessment for Opioids ,
Meeting of the Committee on Pain Management and Regulatory Strategies to
Address Prescription Opioid Abuse Keck Center, Washington, DC. Retrieved

[19] (July 22, 2016). Comprehensive Addiction and Recovery Act (CARA) - Public
Law 114–198. Retrieved from:


[40] North Carolina Translational and Clinical Sciences Institute. Source: https://tracs.unc.edu/


